Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency

Open access
Baumgartner-Parzer, Sabina, Witsch-Baumgartner, Martina, Hoeppner, Wolfgang · 2020 · European Journal of Human Genetics

Abstract

Molecular genetic testing for congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is offered worldwide and is of importance for differential diagnosis, carrier detection and adequate genetic counseling, particularly for family planning. In 2008 the European Molecular Genetics Quality Network (EMQN) for the first time offered a European-wide external quality assessment scheme for CAH (due to 21-OH deficiency). The interest was great and over the last years at about 60 laboratories from Europe, USA and Australia regularly participated in that scheme. These best practice guidelines were drafted on the basis of the extensive knowledge and experience got from those annually organized CAH-schemes. In order to obtain the widest possible consultation with practicing laboratories the draft was therefore circulated twice by EMQN to all laboratories participating in the EQA-scheme for CAH genotyping and was updated by that input. The present guidelines address quality requirements for diagnostic molecular genetic laboratories, as well as criteria for CYP21A 2 genotyping (including carrier-testing and prenatal diagnosis). A key aspect of that article is the use of appropriate methodologies (e.g., sequencing methods, MLPA (multiplex ligation dependent probe amplification), mutation specific assays) and respective limitations and analytical accuracy. Moreover, these guidelines focus on classification of variants, and the interpretation and standardization of the reporting of CYP21A2 genotyping results. In addition, the article provides a comprehensive list of common as well as so far unreported CYP21A2-variants.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41431-020-0653-5

Cites

Statistics

Figures

Fig. 1 Flow chart of CYP21A2 genotyping. *Best practice genotyping should be PCR-based sequence analysis along with MLPA as addressed in 6.1. of the manuscript. **Second pathogenic variant in trans not detected.
Fig. 1 Flow chart of CYP21A2 genotyping. *Best practice genotyping should be PCR-based sequence analysis along with MLPA as addressed in 6.1. of the manuscript. **Second pathogenic variant in trans not detected.CC BY · PubMed Central
Fig. 2 Illustration of a monomodular and a standard bimodular RCCX-unit, composed of the functional CYP21A2 gene, the CYP21A1P pseudogene and their neighboring genes tenascin TNXA/B, complement component 4A/B and the serine/threonine nuclear protein kinase RP. The close proximity of CYP21A2 and CYP21A1P as well as copy number variations for this RCCX- locus could result in a deletion of a 30 kb region (including the CYP21A2 gene) due to unequal crossing-over (misalignment of a CYP21A1P pseudogene to the functional CYP21A2 gene) between chromosomes with a monomodular and a standard bimodular form.
Fig. 2 Illustration of a monomodular and a standard bimodular RCCX-unit, composed of the functional CYP21A2 gene, the CYP21A1P pseudogene and their neighboring genes tenascin TNXA/B, complement component 4A/B and the serine/threonine nuclear protein kinase RP. The close proximity of CYP21A2 and CYP21A1P as well as copy number variations for this RCCX- locus could result in a deletion of a 30 kb region (including the CYP21A2 gene) due to unequal crossing-over (misalignment of a CYP21A1P pseudogene to the functional CYP21A2 gene) between chromosomes with a monomodular and a standard bimodular form.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 229 · Cited by 110

Research works printed but not linked: 9

  1. Tardy V. Management of pregnancies at risk of 21-hydroxylase or 11-hydroxylase deficiency using fetal sex determination in maternal serum proposed in France since 2002: how to limit prenatal exposure to dexamethasone. Horm Res. 2009;70(Suppl 3):348.
  2. Tardy V. Gene symbol: CYP21A2. Disease: steroid 21-hydroxylase deficiency. Hum Genet. 2006;119/3:363.
  3. Tardy VT, Morel Y. Gene symbol: CYP21A2. Hum Genet. 2007;121/2:293–4.
  4. Speiser PW, New MI, White PC. Molecular genetic analysis of nonclassic steriod 21-hydroxylase deficiency associated with HLA-B14,DR1. N Engl J Med. 1988;319/1:19–23. · DOI · Paper page
  5. Bleicken C, Loidi L, Dhir V, Parajes S, Quinteiro C, Dominguez F, et al. Functional characterization of three CYP21A2 sequence variants (p.A265V, p.W302S, p.D322G) employing a yeast co-expression system. Hum Mutat. 2009;30(Feb):E443–50. https://doi.org/10.1002/humu.20926. · DOI · Paper page
  6. Baradaran-Heravi A, Vakili R, Robins T, Carlsson J, Ghaemi N, Aʼrabi A, et al. Three novel CYP21A2 mutations and their protein modelling in patients with classical 21-hydroxylase deficiency from northeastern Iran. Clin Endocrinol (Oxf). 2007;67/3:335–41. · DOI
  7. Baumgartner-Parzer SM, Schulze E, Waldhäusl W, Pauschenwein S, Rondot S, Nowotny P, et al. Mutational spectrum of the steroid 21-hyxdroxylase gene in Austria: identification of a novel missense mutation. J Clin Endocrinol Metab. 2001;86/10:4771–5. · DOI · Paper page
  8. Ordoñez-Sánchez ML, Ramírez-Jiménez S, López-Gutierrez AU, Riba L, Gamboa-Cardiel S, Cerrillo-Hinojosa M, et al. Molecular genetic analysis of patients carrying steroid 21-hydroxylase deficiency in the Mexican population: identification of possible new mutations and high prevalence of apparent germ-line mutations. Hum Genet. 1998;102/2:170–7.
  9. Wedell A, Luthman H. Steroid 21-hydroxylase (P450c21): a new allele and spread of mutations through the pseudogene. Hum Genet. 1993;91/3:236–40.

Metadata

Authors
Baumgartner-Parzer, S., Witsch-Baumgartner, M., & Hoeppner, W.
Affiliations
  • Medical University of Vienna (AT)
  • Bioglobe (Germany) (DE)
Corresponding author
Baumgartner-Parzer, Sabina
Venue
European Journal of Human Genetics
Published
2020-07-02
Volume
28
Issue
10
Pages
1341-1367
ISSN
  • 1018-4813 (ISSN-L)
  • 1476-5438
OpenAlex
W3039819996
Cited by
110
References
229
Citations by year
2026: 14 · 2025: 27 · 2024: 20 · 2023: 18 · 2022: 12 · 2021: 19
FWCI
3.97
Type
journal article
Language
en
Open access
Licence
Locations
  • European Journal of Human Genetics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
21-hydroxylase deficiency, congenital adrenal hyperplasia, molecular genetic testing, external quality assessment, variant interpretation, genetic counseling, carrier screening, prenatal diagnosis, multiplex ligation-dependent probe amplification, variant reporting
MeSH terms
Adrenal Hyperplasia, Congenital, Consensus Statements as Topic, Europe, Genetic Testing, Humans, Quality Assurance, Health Care, Databases, Factual, Practice Guidelines as Topic, Cytochrome P-450 CYP1A2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency. https://app.cochat.ai/papers/10.1038/s41431-020-0653-5
The paper
Baumgartner-Parzer, S., Witsch-Baumgartner, M., & Hoeppner, W. (2020). EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency. European Journal of Human Genetics. https://doi.org/10.1038/s41431-020-0653-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.